HOME >> BIOLOGY >> NEWS
Vax and Pax: Taking turns to build an eye

Opposing ball clubs don't take the field at the same time, and neither do teams of proteins responsible for creating the eye. While one team builds the retina, in adjacent cellular turf the opponents are busy constructing the cord that carries visual signals to the brain. And these guys aren't supposed to mingle.

That's why researchers at the Salk Institute for Biological Studies were surprised to find the respective team captains--Vax2, a protein that along with Vax1 builds the optic nerve cord, and Pax6, a protein that drives retinal fate--playing on the same field. That puzzle is explained in a forthcoming paper in Genes and Development.

Earlier studies from the laboratory of Greg Lemke, Ph.D., professor in Salk's Molecular Neurobiology Laboratory, had shown that Vax2 antagonized Pax6. "We knew that Vax1 and 2 acted together to inactivate Pax6. That's how you get an optic nerve--by preventing it from becoming a retina," explains Lemke. The only problem was that later on both Vax2 and Pax6 were co-expressed in the same cells. "If Vax2 was repressing Pax6 this seemed inconsistent," he says.

Both proteins bind DNA and function in a cell's nucleus to switch genes on and off. Pax6 regulates the development of the retina, while Vax2 ensures that the optic nerve gets built. Finding both proteins in the same nucleus would make about as much sense as having runners for the Giants and the Dodgers on base at the same time.

Analyzing eye development in both mouse and chick tissues, Lemke and former postdoctoral fellow Jin Woo Kim, Ph.D., solved the mystery. Stina Mui, a former graduate student in the Lemke lab had originally observed Vax2 in the cytoplasm of cultured cell lines and Kim had taken on the task of figuring out why. He showed that Vax2 protein is indeed expressed in the same retinal cells as Pax6, but that Vax2 shuttles in and out of the nucleus in response to a signaling molecule known as Sonic hedgehog.

"Va
'"/>

Contact: Gina Kirchweger
kirchweger@salk.edu
858-453-4100 x1340
Salk Institute
14-Oct-2006


Page: 1 2 3

Related biology news :

1. Taking a supplement of glycine helps prevent degenerative diseases such as arthrosis or osteoporosis
2. Taking heart failure to the MAT1
3. Taking chips to the next level of gene hunting
4. Taking evolutions temperature: Researchers pinpoint the energy it takes to make a species
5. Taking a bite out of a fellow worker helps wasps recruit new foragers
6. Taking a break from fractures: A closer look at vitamin D
7. Taking a flying jump
8. Taking the piste out of Alpine vegetation
9. Taking the next step toward growing our own fuel
10. OHSU turns mouse into factory for human liver cells
11. Leukemia drug turns mini-molecules up, cancer genes down

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Vax and Pax Taking turns build eye

(Date:4/10/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cjk4gb/security ) has ... - NEC" report to their offering. ... to supply a range of IT security management and ... on the development of a Big Data and cloud ... Asia-Pacific region is a core ...
(Date:4/8/2015)... , April 8, 2015  Infinisource, a leading ... services, and Morpho, a leading supplier of biometric ... produce the market,s most advanced biometrically-enabled time clock, ... NXG time clock is setting a bold, new ... data for the small and mid-size employer. When ...
(Date:4/2/2015)... Germany , April 2, 2015 ... fingerprint tests DERMALOG by far outperforms the strongest ... always maintaining high accuracy, the system is capable ... Hence, the speed proves up to be ten ... faster than its runner-up performance.      ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
(Date:5/27/2015)... , May 27, 2015  Tikcro Technologies Ltd. ... ended March 31, 2015. Aviv ... we continued pre-clinical work to generate functional specific antibodies, ... early stage, we are encouraged by the development progress. ... as new antibodies which modulate immune checkpoints gain clinical ...
(Date:5/27/2015)... Calif. , May 27, 2015  CytomX, ... treatment of cancer, today announced the appointments of ... and Cynthia Ladd as senior vice ... Goeltz was chief financial officer of Onyx Pharmaceuticals, ... an independent consultant and legal counsel to several ...
(Date:5/27/2015)... THOUSAND OAKS, Calif. , May 27, 2015 /PRNewswire/ ... company, has been awarded a U.S. patent for a ... gene in areas such as research, product development and ... useful in regulating key biosynthetic processes that are the ... to offer other seed companies a commercial license to ...
(Date:5/27/2015)... Madison, NJ (PRWEB) May 27, 2015 ... for evaluating the impact of regulation on medical innovation, ... Centered Innovation (iPCI) of Fairleigh Dickinson University’s ( ... inaugural MI3 Alert pertains to new FDA ... Senate proposal for accelerating the approval of certain medical ...
Breaking Biology Technology:Tikcro Technologies Reports First Quarter 2015 Results 2Tikcro Technologies Reports First Quarter 2015 Results 3CytomX Expands Executive Leadership Team 2CytomX Expands Executive Leadership Team 3Ceres Awarded Patent for Innovation in Soybean 2Ceres Awarded Patent for Innovation in Soybean 3Medical Innovation Impact Index Launched at Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) under the Rothman Institute 2
Cached News: